comparemela.com

Latest Breaking News On - Jonathan finn - Page 1 : comparemela.com

Atossa Therapeutics (NASDAQ:ATOS) Shares Pass Above Two Hundred Day Moving Average of $1.13

Atossa Therapeutics, Inc. (NASDAQ:ATOS – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.13 and traded as high as $1.55. Atossa Therapeutics shares last traded at $1.46, with a volume of 1,163,998 shares traded. Wall Street Analysts Forecast Growth […]

Jonathan-finn
Connor-clark-lunn-investment-management-ltd
Cetera-advisors
Atossa-therapeutics-company-profile
Atossa-therapeutics-inc
Vanguard-group-inc
Virtu-financial
Cantor-fitzgerald
Securities-exchange-commission
Nasdaq
Atossa-therapeutics
Get-free-report

Cantor Fitzgerald Reiterates Overweight Rating for Atossa Therapeutics (NASDAQ:ATOS)

Cantor Fitzgerald reissued their overweight rating on shares of Atossa Therapeutics (NASDAQ:ATOS – Free Report) in a research note published on Tuesday morning, Benzinga reports. A number of other brokerages have also weighed in on ATOS. HC Wainwright lifted their price target on shares of Atossa Therapeutics from $4.00 to $6.00 and gave the company […]

Jonathan-finn
Cantor-fitzgerald
Connor-clark-lunn-investment-management-ltd
Atossa-therapeutics-inc
Atossa-therapeutics-company-profile
Vanguard-group-inc
Atossa-therapeutics
Free-report
Get-free-report
Director-jonathan-finn
Lunn-investment-management
Atossa-therapeutics-daily

StockNews.com Upgrades Atossa Therapeutics (NASDAQ:ATOS) to Hold

StockNews.com upgraded shares of Atossa Therapeutics (NASDAQ:ATOS – Free Report) from a sell rating to a hold rating in a research note published on Tuesday. A number of other research analysts have also recently commented on ATOS. HC Wainwright boosted their target price on shares of Atossa Therapeutics from $4.00 to $6.00 and gave the […]

Jonathan-finn
Securities-exchange-commission
Vanguard-group-inc
Nasdaq
Atossa-therapeutics-inc
Connor-clark-lunn-investment-management-ltd
Cantor-fitzgerald
Atossa-therapeutics-company-profile
Atossa-therapeutics
Free-report
Get-free-report
Director-jonathan-finn

HC Wainwright Raises Atossa Therapeutics (NASDAQ:ATOS) Price Target to $6.00

Atossa Therapeutics (NASDAQ:ATOS – Free Report) had its target price upped by HC Wainwright from $4.00 to $6.00 in a research report released on Monday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Atossa Therapeutics’ Q2 2024 earnings at ($0.05) EPS, Q3 2024 earnings […]

Jonathan-finn
Atossa-therapeutics-inc
Securities-exchange-commission
Atossa-therapeutics-company-profile
Connor-clark-lunn-investment-management-ltd
Vanguard-group-inc
Atossa-therapeutics
Free-report
Get-free-report
Director-jonathan-finn
Exchange-commission
Lunn-investment-management

Atossa Therapeutics (NASDAQ:ATOS) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Atossa Therapeutics (NASDAQ:ATOS – Get Free Report) posted its earnings results on Monday. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02, Zacks reports. Atossa Therapeutics Trading Up 4.5 % NASDAQ:ATOS opened at $1.61 on Thursday. The stock has a 50 day moving average of $1.59 and a […]

Jonathan-finn
Securities-exchange-commission
Cantor-fitzgerald
Atossa-therapeutics-company-profile
Atossa-therapeutics-inc
Nasdaq
Atossa-therapeutics
Get-free-report
Director-jonathan-finn
Exchange-commission
Atossa-therapeutics-daily

vimarsana © 2020. All Rights Reserved.